150 related articles for article (PubMed ID: 24256569)
1. Design of long circulating nontoxic dendritic polymers for the removal of iron in vivo.
Imran ul-haq M; Hamilton JL; Lai BF; Shenoi RA; Horte S; Constantinescu I; Leitch HA; Kizhakkedathu JN
ACS Nano; 2013 Dec; 7(12):10704-16. PubMed ID: 24256569
[TBL] [Abstract][Full Text] [Related]
2. In vitro chelating, cytotoxicity, and blood compatibility of degradable poly(ethylene glycol)-based macromolecular iron chelators.
Rossi NA; Mustafa I; Jackson JK; Burt HM; Horte SA; Scott MD; Kizhakkedathu JN
Biomaterials; 2009 Feb; 30(4):638-48. PubMed ID: 18977029
[TBL] [Abstract][Full Text] [Related]
3. In vivo efficacy, toxicity and biodistribution of ultra-long circulating desferrioxamine based polymeric iron chelator.
Hamilton JL; Imran Ul-Haq M; Abbina S; Kalathottukaren MT; Lai BF; Hatef A; Unniappan S; Kizhakkedathu JN
Biomaterials; 2016 Sep; 102():58-71. PubMed ID: 27322959
[TBL] [Abstract][Full Text] [Related]
4. Influence of architecture of high molecular weight linear and branched polyglycerols on their biocompatibility and biodistribution.
Imran ul-haq M; Lai BF; Chapanian R; Kizhakkedathu JN
Biomaterials; 2012 Dec; 33(35):9135-47. PubMed ID: 23020861
[TBL] [Abstract][Full Text] [Related]
5. Iron Binding and Iron Removal Efficiency of Desferrioxamine Based Polymeric Iron Chelators: Influence of Molecular Size and Chelator Density.
Hamilton JL; Ul-Haq MI; Creagh AL; Haynes CA; Kizhakkedathu JN
Macromol Biosci; 2017 Mar; 17(3):. PubMed ID: 27683190
[TBL] [Abstract][Full Text] [Related]
6. Long-circulating non-toxic blood pool imaging agent based on hyperbranched polyglycerols.
Saatchi K; Gelder N; Gershkovich P; Sivak O; Wasan KM; Kainthan RK; Brooks DE; Häfeli UO
Int J Pharm; 2012 Jan; 422(1-2):418-27. PubMed ID: 22044540
[TBL] [Abstract][Full Text] [Related]
7. Hybrid polyglycerols with long blood circulation: synthesis, biocompatibility, and biodistribution.
Imran ul-haq M; Lai BF; Kizhakkedathu JN
Macromol Biosci; 2014 Oct; 14(10):1469-82. PubMed ID: 25045070
[TBL] [Abstract][Full Text] [Related]
8. Conjugation of aurein 2.2 to HPG yields an antimicrobial with better properties.
Kumar P; Shenoi RA; Lai BF; Nguyen M; Kizhakkedathu JN; Straus SK
Biomacromolecules; 2015 Mar; 16(3):913-23. PubMed ID: 25664972
[TBL] [Abstract][Full Text] [Related]
9. In vivo circulation, clearance, and biodistribution of polyglycerol grafted functional red blood cells.
Chapanian R; Constantinescu I; Brooks DE; Scott MD; Kizhakkedathu JN
Biomaterials; 2012 Apr; 33(10):3047-57. PubMed ID: 22261097
[TBL] [Abstract][Full Text] [Related]
10. Nanogel-DFO conjugates as a model to investigate pharmacokinetics, biodistribution, and iron chelation in vivo.
Wang Y; Liu Z; Lin TM; Chanana S; Xiong MP
Int J Pharm; 2018 Mar; 538(1-2):79-86. PubMed ID: 29341909
[TBL] [Abstract][Full Text] [Related]
11. Enzymatically Biodegradable Polyrotaxane-Deferoxamine Conjugates for Iron Chelation.
Liu Z; Lin TM; Purro M; Xiong MP
ACS Appl Mater Interfaces; 2016 Oct; 8(39):25788-25797. PubMed ID: 27623539
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable polyglycerols with randomly distributed ketal groups as multi-functional drug delivery systems.
Shenoi RA; Lai BF; Imran ul-haq M; Brooks DE; Kizhakkedathu JN
Biomaterials; 2013 Aug; 34(25):6068-81. PubMed ID: 23688604
[TBL] [Abstract][Full Text] [Related]
13. Removal of thallium by combining desferrioxamine and deferiprone chelators in rats.
Amiri A; Fatemi SJ; Fatemi SN
Biometals; 2007 Apr; 20(2):159-63. PubMed ID: 16927173
[TBL] [Abstract][Full Text] [Related]
14. Exploring the "iron shuttle" hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture.
Link G; Konijn AM; Breuer W; Cabantchik ZI; Hershko C
J Lab Clin Med; 2001 Aug; 138(2):130-8. PubMed ID: 11477380
[TBL] [Abstract][Full Text] [Related]
15. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
[TBL] [Abstract][Full Text] [Related]
17. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
Payne KA; Rofail D; Baladi JF; Viala M; Abetz L; Desrosiers MP; Lordan N; Ishak K; Proskorovsky I
Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
[TBL] [Abstract][Full Text] [Related]
18. Design of Safe Nanotherapeutics for the Excretion of Excess Systemic Toxic Iron.
Abbina S; Abbasi U; Gill A; Wong K; Kalathottukaren MT; Kizhakkedathu JN
ACS Cent Sci; 2019 May; 5(5):917-926. PubMed ID: 31139728
[TBL] [Abstract][Full Text] [Related]
19. Modulation of deferoxamine toxicity and clearance by covalent attachment to biocompatible polymers.
Hallaway PE; Eaton JW; Panter SS; Hedlund BE
Proc Natl Acad Sci U S A; 1989 Dec; 86(24):10108-12. PubMed ID: 2481311
[TBL] [Abstract][Full Text] [Related]
20. Hyperbranched polyglycerols as trimodal imaging agents: design, biocompatibility, and tumor uptake.
Saatchi K; Soema P; Gelder N; Misri R; McPhee K; Baker JH; Reinsberg SA; Brooks DE; Häfeli UO
Bioconjug Chem; 2012 Mar; 23(3):372-81. PubMed ID: 22304718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
